All Videos

ORKA-001 builds on the proven success of existing IL-23 inhibitors used in psoriasis treatment.

Lisa Espinoza, MD, discusses key insights from Allergan's Hyaluronic Acid Injectable Fillers Report, highlighting patient satisfaction and evolving aesthetic trends.

Explore insights from Renata Block DMSc, MMS, PA-C, and James Del Rosso, DO, on interpreting clinical trial data in dermatology for enhanced patient care and outcomes.

Panelists discuss how melasma diagnosis requires identifying specific location patterns, absence of scale, avoidance of eyelid areas, and using Wood lamp examination to differentiate between superficial and deep melasma while distinguishing it from other pigmentary conditions such as postinflammatory hyperpigmentation and solar lentigines.

Panelists discuss how melasma is a chronic disease caused by the interplay of hormones, sunlight, heat, and genetic predisposition, emphasizing that prevention through comprehensive sun protection including daily sunscreen use (particularly tinted mineral formulations), avoiding peak sun hours, wearing protective clothing, and considering oral supplements is essential for managing this condition that requires lifelong treatment rather than a cure.

Many HS patients still require more aggressive or advanced treatments due to incomplete response to current options.

Mary W. Chang, MD, discusses the expanded FDA approval of ruxolitinib cream for children with atopic dermatitis and its role in addressing treatment gaps, safety, and real-world use.

Panelists discuss how the OX40-OX40L costimulatory pathway represents a promising upstream target for atopic dermatitis treatment by modulating T-cell survival, expansion, and memory formation rather than targeting downstream cytokines.

A panelist highlights emerging therapies such as phosphodiesterase-4 (PDE4) and topical Janus kinase (JAK) inhibitors that target shared inflammatory pathways across skin diseases, emphasizing their potential to simplify and improve seborrheic dermatitis management with safer, more convenient options and a promising pipeline of treatments on the horizon.

Panelists discuss how atopic dermatitis involves complex T-cell–mediated immune dysfunction beyond just Th2 pathways, with antigen-presenting cells driving naive T-cell activation and differentiation into multiple T-cell subsets that produce various inflammatory cytokines.

Panelists discuss the benefits of hydrophobically modified polymer surfactants, highlighting their gentle cleansing action that effectively removes impurities while preserving the skin barrier, making them ideal for sensitive and compromised skin.

Panelists discuss the importance of choosing gentle, pH-balanced surfactants in cleansers to protect the skin barrier while balancing patient preferences for foaming and sensory experiences.

Derm Dispatch host Renata Block, DMSc, MMS, PA-C, and Buchi Neita, MCMSc, PA-C, discuss how to revolutionize dermatology with lifestyle medicine, enhancing skin health and overall well-being.

This episode explores the controversy and lack of clear diagnostic criteria for TSW.

Jorge Garcia-Zuazaga, MD, MBA, FAAD, FACMS, shares how Apex Skin’s multi-site model advances clinical trial access, diversity, and execution.

Elena Hawryluk, MD, PhD, shares groundbreaking insights on pediatric dermatology and melanoma management at Maui Derm NP+PA, emphasizing innovative treatments.

By targeting IL-13, APG777 may allow for less frequent dosing compared to existing biologics.

Discover educational insights on blistering diseases and innovative treatments like dupilumab at the Maui Derm NP+PA Fall 2025 conference.

Kara Mudd, PA-C, shares vital insights on atopic dermatitis, rosacea, and contact dermatitis from Maui Derm NP+PA Fall 2025, enhancing clinical practice.

Walter Liszewski, MD, shares innovative and personalized treatment strategies for managing atopic and contact dermatitis at Maui Derm NP+PA Fall 2025.

Discover key insights from Maui Derm NP+PA Fall 2025 on acne and rosacea treatments, featuring expert strategies from Hilary Baldwin, MD.

Discover the latest advancements in pediatric dermatology and atopic dermatitis treatments from Maui Derm NP+PA Fall 2025, featuring expert insights and emerging therapies.

Stephanie Simmerman, DNP, APRN-C, led discussions on psoriasis treatment innovations at Maui Derm NP+PA Fall 2025, highlighting NP and PA advancements.

George Martin, MD, reveals cutting-edge treatments for vitiligo, psoriasis, and psoriatic arthritis at Maui Derm NP+PA Fall 2025, enhancing patient care strategies.

Discover expert insights on treating uncommon conditions like lichen planus, CSU, and polymorphous light eruption from Maui Derm NP+PA Fall 2025.

Panelists discuss how atopic dermatitis exhibits tremendous heterogeneity in clinical presentation, disease course, symptom variability, environmental triggers, and underlying immunologic and genetic factors that contribute to the challenge of developing one-size-fits-all treatments.

A panelist discusses a case of moderate seborrheic dermatitis in a 34-year-old African American woman, emphasizing the need for individualized, culturally sensitive treatment plans that accommodate hair type and styling preferences, illustrating how an intermittent ketoconazole shampoo regimen aligned with her routine led to symptom improvement.

Panelists discuss how despite recent therapeutic advances in atopic dermatitis treatment, significant unmet needs remain including partial responses, lack of long-term stable control, and the need for broader patient response rates and deeper clearance levels.

Discover expert insights on cutaneous oncology from George Martin, MD, focusing on innovative treatments for skin cancers at Maui Derm NP+PA Fall.

Discover key insights from the Maui Derm NP+PA Fall 2025 Conference on advances in dermatology, including new treatments and research findings.